betahistine stada 24 mg tablett
stada arzneimittel ag - betahistindihydroklorid - tablett - 24 mg - mannitol hjälpämne; betahistindihydroklorid 24 mg aktiv substans
betahistine stada 8 mg tablett
stada arzneimittel ag - betahistindihydroklorid - tablett - 8 mg - betahistindihydroklorid 8 mg aktiv substans; mannitol hjälpämne
betahistine stada 16 mg tablett
stada arzneimittel ag - betahistindihydroklorid - tablett - 16 mg - mannitol hjälpämne; betahistindihydroklorid 16 mg aktiv substans
betahistine sandoz 8 mg tablett
sandoz a/s - betahistindihydroklorid - tablett - 8 mg - betahistindihydroklorid 8 mg aktiv substans; laktosmonohydrat hjälpämne
betahistine sandoz 16 mg tablett
sandoz a/s - betahistindihydroklorid - tablett - 16 mg - betahistindihydroklorid 16 mg aktiv substans; laktosmonohydrat hjälpämne
orladeyo
biocryst ireland limited - berotralstat dihydrochloride - angioödemar, ärftlig - other hematological agents - orladeyo is indicated for routine prevention of recurrent attacks of hereditary angioedema (hae) in adult and adolescent patients aged 12 years and older.
ceplene
laboratoires delbert - histamin dihydrochloride - leukemi, myeloid, akut - immunstimulatorer, - ceplene maintenance therapy is indicated for adult patients with acute myeloid leukaemia in first remission concomitantly treated with interleukin-2 (il-2). effekten av ceplene har inte visats fullständigt hos patienter som är äldre än 60 år.
cufence
univar solutions bv - trientin dihydrochloride - hepatolentikulär degeneration - andra matsmältningsorgan och ämnesomsättning produkter, - cufence är indicerat för behandling av wilsons sjukdom hos patienter intoleranta mot d-penicillamin behandling, vuxna och barn som är 5 år eller äldre.
inrebic
bristol myers squibb pharma eeig - fedratinib dihydrochloride monohydrate - myeloproliferative disorders; primary myelofibrosis - antineoplastiska medel - inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are janus associated kinase (jak) inhibitor naïve or have been treated with ruxolitinib.
sapropterin dipharma
dipharma arzneimittel gmbh - sapropterin dihydrochloride - phenylketonurias - andra matsmältningsorgan och ämnesomsättning produkter, - sapropterin dipharma is indicated for the treatment of hyperphenylalaninaemia (hpa) in adults and paediatric patients of all ages with phenylketonuria (pku) who have been shown to be responsive to such treatment. sapropterin dipharma is also indicated for the treatment of hyperphenylalaninaemia (hpa) in adults and paediatric patients of all ages with tetrahydrobiopterin (bh4) deficiency who have been shown to be responsive to such treatment.